Cell to Cure ApS
CVR 39401975 · Private limited company (ApS) · Active · Low risk
Cell to Cure ApS is a Private limited company (ApS), founded on , based in Birkerød. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 1.0% over the next 12 months, which is 0.7 times the average for Danish companies. 7 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK -1.2m and a net result of DKK -9.8m. CEO: Annette Ekblond, Mandana Haack-Sørensen, Martin Roland Jensen.
Bankruptcy risk for Cell to Cure ApS
0.7 × the average (1.41%) · higher risk than 72% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 39401975
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (8 years)
- Address
- c/o Jens Kastrup, Kajerødgård 9
3460 Birkerød - Municipality
- Rudersdal
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 120k
- Auditor
- Deloitte Statsautoriseret Revisionspartnerselskab
- Audit opted out
- Yes
Warning signs
| Annual reports filed late | 0 of 7 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -12.3% |
| Current ratio | 49% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 1 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 1 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -3.1m | DKK -2.6m |
| Net profit | DKK -9.8m | DKK -7.0m |
| Equity | DKK -1.2m | DKK 3.1m |
| Total assets | DKK 9.6m | DKK 6.1m |
| Cash | DKK 193k | – |
| Short-term debt | DKK 10.8m | – |
| Avg. employees | 12 | – |
Latest annual report: Reporting class B · auditor's statement: Andre erklæringer uden sikkerhed · Deloitte Statsautoriseret Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 142 | ||
| 1 Sep 2023 – 31 Dec 2024 | 139 | ||
| 1 Sep 2022 – 31 Aug 2023 | 78 | ||
| 1 Sep 2021 – 31 Aug 2022 | 182 | ||
| 1 Sep 2020 – 31 Aug 2021 | 87 | ||
| 1 Sep 2019 – 31 Aug 2020 | 67 | ||
| 7 Mar 2018 – 31 Aug 2019 | 76 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Annette Ekblond | Current | |
| CEO | Mandana Haack-Sørensen | Current | |
| CEO | Martin Roland Jensen | Current | |
| Board | Annette Ekblond | Current | |
| Board | Jens Kastrup | Current | |
| Board | Mandana Haack-Sørensen | Current | |
| Board | Anders Østergaard | Current | |
| Board | Martin Roland Jensen | Current | |
| Board | Martin Roland Jensen | ||
| Board | Jesper Kihl | ||
| Owner (5%) | MEDIC ADVICE ApS | Current | |
| Owner (50%) | Endeavour Cells ApS | Current | |
| Owner (10%) | Ekblond.ApS | Current | |
| Owner (10%) | JKastrup.ApS | Current | |
| Owner (10%) | LMN.ApS | Current | |
| Owner (33%) | Ekblond.ApS | ||
| Owner (33%) | JKastrup.ApS | ||
| Owner (33%) | LMN.ApS | ||
| Owner (5%) | MEDIC ADVICE ApS | ||
| Owner (25%) | Ekblond.ApS | ||
| Owner (25%) | JKastrup.ApS | ||
| Owner (25%) | LMN.ApS | ||
| Owner (10%) | MEDIC ADVICE ApS | ||
| Founder | Ekblond.ApS | Current | |
| Founder | JKastrup.ApS | Current | |
| Founder | LMN.ApS | Current |
The CEOs' other companies
Annette Ekblond – 1 other companies
- Ekblond.ApS Active
Mandana Haack-Sørensen – 1 other companies
- LMN.ApS Active
Martin Roland Jensen – 7 other companies, of which 1 bankrupt
- CYTOVAC A/S Bankrupt 18 Mar 2025
- AdaptVac ApS Active
- EXPRES2ION BIOTECHNOLOGIES ApS Active
- EXPRES2ION HOLDING ApS Fusioneret
- MEDIC ADVICE ApS Active
- MEDIC ADVICE ApS Opløst
- Martin Roland Holding ApS Active
Address history (0 moves)
| c/o Jens Kastrup, Kajerødgård 9, 3460 Birkerød |
Former names
| Cell to Cure ApS | – now |
| Cell2Cure ApS | – |
Other companies at the same address
- JKastrup.ApS Active
Similar companies in Rudersdal
- GigaVax ApS Holte
- Migalis ApS Vedbæk
- LIVAG ApS Vedbæk
- CysBio ApS Hørsholm
- Ceremedy ApS Virum
- JKastrup.ApS Birkerød
- immunAware ApS Hørsholm
- ASTIM Holding ApS Birkerød
- ASRØ Holding ApS Nærum
- Detalo Instruments Aps Birkerød
- ResoTher Pharma A/S Holte
- AVP BioPharma Consult ApS Virum
Questions and answers about Cell to Cure ApS
Has Cell to Cure ApS gone bankrupt?
No, Cell to Cure ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Cell to Cure ApS?
Our model estimates a bankruptcy risk of 1.0% over the next 12 months (low risk), which is 0.7 times the average for Danish companies.
Who is the CEO of Cell to Cure ApS?
Annette Ekblond, Mandana Haack-Sørensen, Martin Roland Jensen are the CEOs of Cell to Cure ApS.
Who is the auditor of Cell to Cure ApS?
Cell to Cure ApS most recently used Deloitte Statsautoriseret Revisionspartnerselskab.
When was Cell to Cure ApS founded?
Cell to Cure ApS was founded on 7 March 2018.
What is the equity of Cell to Cure ApS?
Equity was DKK -1.2m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.